Critical Path Public Private Partnerships Clinical Trials Optional
Food and Drug Administration
At a glance
This funding opportunity is offered by Food and Drug Administration. Awards are up to $20,000,000.
Classification and identifiers
- Solicitation number
- FOR-FD-24-012
- Assistance listing (CFDA)
- 93.103
Amount
$20,000,000
Who can apply
Critical Path Institute
About this opportunity
The FDA seeks an application to continue to maintain, manage existing consortia groups convened and established by the Critical Path Institute. This is a renewal of the cooperative agreement #5U18FD005320 as part of the Critical Path Initiative. This is in support of Critical Path Initiative introduced in Section 566 of the Federal Food, Drug, and Cosmetic Act . This includes developing innovative, collaborative projects in research, education, and outreach for fostering drug product innovation, enabling the acceleration of development, manufacturing, and translational therapeutics, enhancing safety, efficacy, quality, and performance. This funding opportunity will provide support, depending on availability of FDA funding.
Related opportunities
- Comprehensive Partnerships to Advance Cancer Health (CPACH) (U54 Clinical Trial Optional)National Institutes of Health
- Limited Competition: Community-Partnered Nursing Research Centers for Schools and Colleges of Nursing with Limited NIH Funding (P20 Clinical Trial Optional)National Institutes of Health
- SBIR/STTR Commercialization Readiness Pilot (CRP) Program (Parent SB1 Clinical Trial Optional)National Institutes of HealthCloses Apr 2029
- NIH Collaborative International Research Project (Parent PF5 Clinical Trial Optional)National Institutes of HealthCloses May 2029
- REACHing Communities (REACH) Consortium (U01) Clinical Trials OptionalFood and Drug AdministrationUp to $3.0M
- Dental Primary Care Practice-Based Research Network: Clinical Trial or Observational Study Planning and Implementation Cooperative AgreementNational Institutes of Health